Navigation Links
Diagnosoft(R) Secures $4 Million in Financing and Appoints a New President and CEO
Date:1/29/2009

MORRISVILLE, N.C. and PALO ALTO, Calif., Jan. 29 /PRNewswire/ -- Diagnosoft, Inc., an innovator in magnetic resonance (MR) image analysis software that assists in diagnosis, staging and therapeutic monitoring of cardiovascular disease, has announced the closing of $4 million in Series B financing led by Technology Development Fund (TDF) of Cairo, Egypt. The company intends to use the new capital to support further market expansion of Diagnosoft(R) HARP(TM), Diagnosoft(R) PLUS, and Diagnosoft(R) SENC. The capital infusion will also serve to further the development of other innovative MR image analysis technologies designed to increase physician productivity and accuracy, improve patient outcomes, and enhance research and drug development advances.

"When cardiologists and radiologists can make a decision about the condition of a patient's heart based on quantitative data obtained from cardiac MRI analysis, rather than just 'eyeballing' images," said Diagnosoft Co-Founder Dr. Matthias Stuber, "they can come to a faster conclusion that's substantiated, not subjective. When diagnosis and treatment is supported by the numerical data our software provides, it's stronger from a legal standpoint as well."

According to Dr. Jerry Prince, Diagnosoft co-founder and colleague of Dr. Stuber at Johns Hopkins University, "There are many techniques for analyzing the left ventricle of the heart -- ECHO, nuclear medicine, CT, and so -- but we are focused on the emerging technology of MRI for the cardiac market. We are kind of a one-stop shop for innovative analysis of the four magnetic resonance imaging techniques -- CINE, perfusion, delayed enhancement or viability, and function or strain. Diagnosoft is the only company directly looking at function, to see if the heart muscle is contracting properly; consequently, we are the only ones who can put all four imaging techniques together, and present it to the
'/>"/>

SOURCE Diagnosoft, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. BDSI secures US commercial partnership for BEMA Fentanyl with Meda AB
2. Simplex Diabetic Supply, Inc. Secures $50 Million in Growth Equity from New Enterprise Associates
3. UI licensee Optherion secures $37 million in financing
4. IPS Secures National Contract to Deliver FOCUS Healthcare Provider Network Access to Pain Management Specialists
5. Piedmont Pharmaceuticals Secures $8.5 Million Investment
6. NuView Radiopharmaceuticals, Inc. Secures Exclusive Rights From Thomas Jefferson University for a Tumor-Specific Imaging Agent for the Diagnosis of Breast and Prostate Cancers
7. Alexza Secures $50 Million Committed Equity Financing Facility With Azimuth Opportunity, Ltd.
8. Senetek PLC Announces North American Partner for Invicorp(R) Secures Financing for Advancement of Marketing and Development Efforts
9. SpectraScience Secures Distribution for WavSTAT(R) System in Czech Republic
10. InterCure Secures Nationwide Distribution Agreement With Lloyds Pharmacy Group
11. Asoyia Secures Venture Capital Funding

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...ire-USNewswire/ -- Considered a highly risky and c...solid organ transplantation is now a life-saving m...n and women who gathered at the Winspear Opera Hou...m medical centers around the world to celebrate th...nstitute (BRTI), one of the pioneers of solid orga...
(Date:11/27/2009)...ov. 27 Shamir Optical In...ng provider of innovative products and technology ...t its board of directors had declared a dividend d...on (approximately NIS 37.62 million based on the N... or approximately US$ 0.609 (approximately NIS 2.3...
(Date:11/27/2009)... Nov. 27 Allrecipes.com , the w...ving traffic numbers, with more than 2.8 million v...lear picture of what was served on the biggest foo...al in 2009 weighed in at 2,225 calories per servin...cording to the Allrecipes site, Sweet Potato Pie ...
(Date:11/27/2009)...interactive anatomy education apps from Modality a... sciences learning opportunities for iPhone and iP...cus) November 27, 2009 -- Modality, Inc. and Lip...f Wolters Kluwer Health, today announced the avail... App Store. Clemente’s Anatomy, Rohen’...
(Date:11/26/2009)...thiomolybdate (TM) has been shown in studies to be...isease caused by an overload of copper, and certai...tle, however, is known about how the drug works at...western University researchers now has provided an...of TM bound to copper-loaded metallochaperones. Th...
Breaking Medicine News(10 mins):Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 2Health News:Organ Transplant Pioneers Celebrate Baylor Regional Transplant Institute's 25th Anniversary 3Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 2Health News:Shamir Optical Industry Ltd. Announces Declaration of a Cash Dividend 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 2Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 3Health News:It's Black Friday - Time to Shop Off the Calories! Allrecipes Finds Average Thanksgiving Meal Weighed in at 2,225 Calories 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Research sheds light on workings of anti-cancer drug 2Health News:Research sheds light on workings of anti-cancer drug 3
...H, Minn., April 29 ev3 Inc. (Nasdaq:,EVVV) today ...ef executive,officer, is scheduled to present at t...uesday, May 13, 2008 at 4:00 p.m. PT (7:00 p.m. ET...t, go to the investors, section of the ev3 Web sit...
...tate contracts EDS interChange System to manage na...program, New IT solution will administer payments ...th records, help state identify health trends and ...ents, has been awarded a,seven-year, $391 million ...
...rphy Appointed as New Senior Vice President of Con... Pharsight,Corporation (Nasdaq: PHST ), a leadin...regulatory services for optimizing clinical drug,d...es. In this role, Dr. Murphy will lead the Company...
...LE, Tenn., April 29 With an 89% initial success,r...ggressive cancers, a,Nashville-based treatment is ...cording to NeoPlas Innovation Director of Research...en effective,for malignant melanoma, as well as pa...
...rence Call to Occur on Wednesday, April 30 at 2 p....on, Inc.,(Nasdaq: VRML ), a molecular diagnostics... address the need for improved detection of periph...nce will take place on Wednesday, April 30 at 2 p....
...TOWNSHIP, Michigan, April 28 Nearly ten years,aft... three years after FDA,approval, LASIK surgery is ...ered complications or experienced poor outcomes., ...n, to pain, to severe activity-limiting visual hal...
Other Medicine News:Health News:EDS Returns to Georgia With $391 Million Medicaid Win 2Health News:EDS Returns to Georgia With $391 Million Medicaid Win 3Health News:Pharsight Strengthens Senior Management Team 2Health News:Pharsight Strengthens Senior Management Team 3Health News:New Treatment Offers Hope for Beating Aggressive Cancers 2Health News:Vermillion to Host Live Roundtable Discussion With Lead Investigator of its Peripheral Artery Disease Diagnostic Test Program 2Health News:Vermillion to Host Live Roundtable Discussion With Lead Investigator of its Peripheral Artery Disease Diagnostic Test Program 3Health News:Vermillion to Host Live Roundtable Discussion With Lead Investigator of its Peripheral Artery Disease Diagnostic Test Program 4Health News:FDA Examines LASIK Surgery Complications 2
(Date:11/25/2009)...RNewswire-FirstCall/ -- ERT (Nasdaq: ERES ), anno...any,s President and CEO, and Keith Schneck, the Co...duled to present at the 21st Annual Piper Jaffray ...1, 2009 in New York City, New York. ,, Interest... the Company,s corporate website at http://www.er...
(Date:11/25/2009)...ire/ -- BioTrends Research Group, Inc. released Wa...rt, the first in a multi-phase syndicated market r...tho-Biotech,s Stelara, from product launch through...of the report provides quantitative information fr...ation from a subset of 20. The reports assess tri...
(Date:11/25/2009)... 25 For many of the mill... 27 million living with untreated hearing loss , ...logist Cindy Beyer. ,, Dr. Beyer, senior vice p...s largest hearing care and hearing aids companie..., frustration, and social isolation, "which can ea...
Breaking Medicine Technology:ERT to Present at the 21st Annual Piper Jaffray Health Care Conference on December 1, 2009 2Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 2For Millions With Untreated Hearing Loss, Holiday Season Can be Especially Difficult 3MAQUET Cardiovascular Awarded New Contract by Novation 51197 1MAQUET Cardiovascular Awarded New Contract by Novation 51197 2Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration 12954 1Shanghai ChemPartner and Agios Expand Integrated Drug Discovery Research Collaboration 12954 2IDEV Technologies Names Veteran Medical Device Executive Rick Anderson Chairman of the Board of Directors 12952 1IDEV Technologies Names Veteran Medical Device Executive Rick Anderson Chairman of the Board of Directors 12952 2
...ADELPHIA, May 22 Shire plc (LSE: SHP, Nasdaq: ...ompany, announced results of a study showing that ... (lisdexamfetamine dimesylate) CII with the proton... X 2), did not alter the median time it took for m...be reached in the subjects evaluated. In the same...
... ALTO, Calif., May 21 Telik, Inc. (Nasdaq: TELK...mized clinical study of canfosfamide (TELCYTA(R), ...xorubicin (PLD) vs. PLD will be presented at the 4...ical Oncology (ASCO) which will be held from May 2...esentation are as follows: , , , -- Abs...
Other Medicine Technology:New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 2New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 3New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 4New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 5New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 6New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 7New Study Evaluating the ADHD Medication VYVANSE(R) (lisdexamfetamine dimesylate) CII Demonstrated No Change in the Pharmacokinetic Profile of VYVANSE When Coadministered with Prilosec OTC(R) 40 mg (20 mg X 2), a Commonly Used Proton Pump Inhibitor (PPI) 8
Curved Dressing Forceps With Serrations
Troutman-Barraquer Corneal Utility Forceps, Colibri Style - 0.5 mm
Catalano Corneal Scleral Forceps
Troutman-Barraquer Corneal Utility Forceps, Colibri Style
Medicine Products: